letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...1011121314151617181920...100101»
  • ||||||||||  letrozole / Generic mfg.
    Journal, IO biomarker:  Alleviation of adipose-hepatic glycolipid dysregulation by acetate in experimental PCOS model is associated with NF-?B/NLRP3 repression. (Pubmed Central) -  Dec 4, 2023   
    Female Wistar rats (8-week-old) were randomly allocated into four groups of n?=6/group, which received vehicle, sodium acetate (200?mg), letrozole (1?mg/kg), and letrozole plus sodium acetate, respectively...Nonetheless, concomitant acetate supplementation attenuated these derangements. The present data collectively suggest that acetate ameliorates adipose-hepatic glycolipid dysregulation in experimental PCOS model by attenuating androgen excess and NF-?B/NLRP3 immunoreactivity.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
    Journal:  Chemical Application of Topological Indices in Infertility Treatment Drugs and QSPR Analysis. (Pubmed Central) -  Dec 4, 2023   
    We compute the topological descriptors with the limiting behaviors associated with these pharmaceutical drugs and offer degree-based topological parameters for them. We conducted a QSPR investigation on the prospective degree-based topological descriptors using quadratic, cubic, exponential, and logarithmic regression models.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date, Adverse events:  Vitamin D and Calcium Supplementation in Breast Cancer (clinicaltrials.gov) -  Nov 30, 2023   
    P2/3,  N=40, Recruiting, 
    Hence, beads based on chitosan and sodium alginate were successfully synthesized and can be used for the controlled release of letrozole. Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
  • ||||||||||  letrozole / Generic mfg.
    Journal, Next-generation sequencing, MSi-H Biomarker:  Outcomes of fertility preservation treatments in patients with endometrial cancer with different molecular classifications based on an NGS panel. (Pubmed Central) -  Nov 30, 2023   
    The combination of gonadotropin-releasing hormone analogues (GnRH-a) and letrozole (HR: 3.43; 95% CI: 1.81-6.52; P< 0.001) was associated with a significantly higher cumulative CR rate...In wild-type TP53 patients, PTEN and PIK3CA mutations significantly prolonged the duration of treatment to achieve CR (log rank P=0.034; P=0.018). The implementation of molecular classification for EC patients undergoing fertility-sparing treatment is promising and can facilitate the selection of appropriate medical regimes to achieve better outcomes in patients with EC who require fertility preservation treatment.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Letrozole combined with rhGH treatment increases the adult height of short pubertal boys. (Pubmed Central) -  Nov 29, 2023   
    The implementation of molecular classification for EC patients undergoing fertility-sparing treatment is promising and can facilitate the selection of appropriate medical regimes to achieve better outcomes in patients with EC who require fertility preservation treatment. Letrozole combined with rhGH treatment is a promising therapy to increase the PAH and FAH of Chinese short pubertal boys.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion, Trial completion date:  Letrozole add-on in the Treatment of Cesarean Scar Pregnancy (clinicaltrials.gov) -  Nov 18, 2023   
    P=N/A,  N=28, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Oct 2023
  • ||||||||||  letrozole / Generic mfg.
    Enrollment closed, Trial primary completion date:  APPOSE: Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis (clinicaltrials.gov) -  Nov 18, 2023   
    P2,  N=65, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Oct 2023 Recruiting --> Active, not recruiting | Trial primary completion date: May 2023 --> Oct 2023
  • ||||||||||  letrozole / Generic mfg.
    Trial completion, Monotherapy:  Monotherapy With Letrozole in Tubal Pregnancy (clinicaltrials.gov) -  Nov 18, 2023   
    P=N/A,  N=22, Completed, 
    Phase classification: P1b/2 --> P1/2 Active, not recruiting --> Completed
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  GOG-3088: Letrozole in Uterine Leiomyosarcoma (clinicaltrials.gov) -  Nov 18, 2023   
    P2,  N=40, Not yet recruiting, 
    Active, not recruiting --> Completed Trial completion date: Oct 2028 --> Jun 2029 | Initiation date: Apr 2023 --> Dec 2023 | Trial primary completion date: Oct 2027 --> Jun 2028
  • ||||||||||  letrozole / Generic mfg., sorafenib / Generic mfg.
    Trial completion, Trial completion date, Metastases:  Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer (clinicaltrials.gov) -  Nov 9, 2023   
    P1/2,  N=52, Completed, 
    However, in the first-line treatment of MBC in Iran, these strategies were not cost-effective compared to Letrozole monotherapy. Active, not recruiting --> Completed | Trial completion date: Oct 2028 --> Apr 2023
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Design and Pharmacophore Study of Triazole Analogues as Aromatase Inhibitors. (Pubmed Central) -  Nov 5, 2023   
    The AI (MT) at 25 mg/kg gel-based feed could therefore be utilised for musculinization without impacting growth, colour, and antioxidant activity of rosy barb, which serves the entire male population in the ornamental fish sector. The additional final SOMFA model created for the interactions between the enzyme & the letrozole blocker may be helpful for future modification and enhancement of the inhibitors of this crucial enzyme.
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg., fulvestrant / Generic mfg.
    A novel ROR1 inhibitor CPD86 suppresses Triple-Negative Breast Cancer cells via regulation of AKT/GSK3? pathway (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1989;    
    CPD86 also represses TNBC cell migration and invasion while leaving non-malignant cells unharmed. This study highlights that ROR1 inhibitors could be developed as a potential therapeutic for TNBC and the data would serve as proof-of-concept justification for evaluation in other ROR1-upregulated cancers.
  • ||||||||||  narazaciclib (ON 123300) / Onconova
    Narazaciclib's differential targets and kinase inhibitory activity contribute to the enhanced inhibition of tumor growth in preclinical models (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1949;    
    P1, P1/2
    Narazaciclib is in Ph I trials; NCT04739293 and CXHL1900340; studying different administration regimens and in endometrial cancer in combination with letrozole (NCT05705505)...Kd values of CDK4/cyclinD1 binding show similar trends; abemaciclib (0.08 nM), narazaciclib (0.18 nM), palbociclib (0.75 nM) and ribociclib (1.3 nM)...Our findings identify important differences generated from assay models studying kinase inhibition, binding and pathway engagement. Understanding the role of the differential targets engaged by narazaciclib, the potential enhanced antitumor immunity and the sensitization by autophagy inhibitors to cell death, will guide future clinical studies.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Treatment with CDK4/6 Inhibitor in a Patient with Metastatic Breast Cancer Causing Myelophthisis (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1915;    
    Studies have examined the in vitro mechanism of bone marrow suppression in Palbociclib versus cytotoxic chemotherapy, and its cytostatic effect on neutrophil precursors allows for hematological toxicities to be transient. With strong supportive care measures, patients in bone marrow visceral crisis can be safely treated with cytopenic CDK4/6 inhibitors.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    LOCOREGIONAL MANAGEMENT OF DE NOVO STAGE IV HORMONE-POSITIVE BREAST CARCINOMA AFTER CDK 4/6 INHIBITOR TREATMENT (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1914;    
    She underwent 4 cycles of chemotherapy with Doxorubicin and Paclitaxel...Patient was then started on Ribociclib plus Letrozole with ovarian function suppression for 18 months...With the advent of newer therapy options like cyclin-dependent kinase 4/6 inhibitors offering outstanding survival benefit for metastatic disease, a more aggressive and synergistic approach with locoregional therapy may be done to eradicate the tumor burden, translating to better long-term survival. Locoregional management of the primary tumor should be discussed in the context of a multidisciplinary team approach and should be individualized based on the individual patient's need.